PERTH, Australia – Singapore-headquartered Cerecin Inc. is gearing up for a series of phase II trials in Australia of its lead compound, tricaprilin, for Alzheimer's disease.
PERTH, Australia – The Australian government's commitment of more than AU$1 billion (US$711 million) to support medical research in cancer and genomics sends the message to investors that the life sciences sector in Australia is sustainable, stakeholders said.
PERTH, Australia – Singapore-headquartered Cerecin Inc. is gearing up for a series of phase II trials in Australia of its lead compound, tricaprilin, for Alzheimer's disease.
PERTH, Australia – The Australian government's commitment of more than AU$1 billion (US$711 million) to support medical research in cancer and genomics sends the message to investors that the life sciences sector in Australia is sustainable, stakeholders said.
PERTH, Australia – Auckland, New Zealand-based CuroNZ has begun a small proof-of-concept study in epilepsy for a cell-penetrating peptide that crosses the blood-brain barrier.
